BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30311182)

  • 1. Auricular Vagus Nerve Stimulation Exerts Antiinflammatory Effects and Immune Regulatory Function in a 6-OHDA Model of Parkinson's Disease.
    Jiang Y; Cao Z; Ma H; Wang G; Wang X; Wang Z; Yang Y; Zhao H; Liu G; Li L; Feng T
    Neurochem Res; 2018 Nov; 43(11):2155-2164. PubMed ID: 30311182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
    Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
    Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
    Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
    Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
    Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
    Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
    Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
    Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
    Xu L; Liu LX; Chen WF; Xie JX; Huang WX
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2008 Feb; 24(1):1-5. PubMed ID: 21141541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model.
    Liu Y; Hao S; Yang B; Fan Y; Qin X; Chen Y; Hu J
    Biochem Pharmacol; 2017 Sep; 140():115-123. PubMed ID: 28551099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
    Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
    Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
    Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
    Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
    Sarookhani MR; Haghdoost-Yazdi H; Sarbazi-Golezari A; Babayan-Tazehkand A; Rastgoo N
    Behav Pharmacol; 2018 Jun; 29(4):336-343. PubMed ID: 29239973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
    Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
    Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
    Inden M; Kitamura Y; Takahashi K; Takata K; Ito N; Niwa R; Funayama R; Nishimura K; Taniguchi T; Honda T; Taira T; Ariga H
    J Pharmacol Sci; 2011; 117(3):189-203. PubMed ID: 22041943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
    Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
    Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.